{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.2.6', 'Known history of testing positive for HIV and CD4 count is below 200 or', 'known acquired immunodeficiency syndrome diagnosis.', '5.2.7', 'Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection', 'at screening (positive HBV surface antigen or detectable HCV RNA if anti-HCV', 'antibody screening test positive) and a detectable viral count at screening.', '5.2.8', 'Use of live virus vaccine within 4 weeks of the first dose of treatment or', 'planned use while on trial for the duration of potential docetaxel treatment. Live', 'vaccine use is acceptable after chemotherapy or for patients randomized to the', 'abiraterone arm. There are no restrictions on inactive viruses.', '5.2.9', 'Known prior severe hypersensitivity to investigational product or any', 'component in its formulations (NCI CTCAE v5.0 Grade > 3).', 'I certify that this patient meets all inclusion and exclusion criteria for enrollment onto this', 'study.', 'Investigator Signature', 'Date', 'Time', 'Page 22 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.3', 'Recruitment Strategies', 'Potential patients will be identified by Investigators in the setting of their outpatient clinics.', '6', 'RANDOMIZATION', 'Patients will be randomized in a 1:1 manner. Patients will be stratified based on Gleason score', '(<8 versus > 8) and the presence of visceral metastasis (yes versus no). Visceral metastasis is', 'defined as liver, lung, or central nervous system (CNS) involvement.', '7', 'TREATMENT PLAN', '7.1', 'Administration Schedule', 'Treatment will occur per standard of care at the discretion of the treating physician. All study', 'drugs will be provided by commercial supply. Study visits will be anchored to day 1 of', 'treatment, without regard for changes to treatment schedule.', 'Patients who are unable to initiate docetaxel or abiraterone therapy within 42 days of', 'randomization will be replaced.', '7.2', 'Docetaxel', '7.2.1', 'How Supplied, Stored, Packaged and Labeled', 'Docetaxel Injection Concentrate is a clear yellow to brownish-yellow viscous solution.', 'Docetaxel is sterile, non-pyrogenic, and is available in single-dose vials containing 20 mg (0.5', 'mL) or 80 mg (2 mL) docetaxel (anhydrous). Each mL contains 40 mg docetaxel (anhydrous)', 'and 1040 mg polysorbate 80.', 'TAXOTERE Injection Concentrate requires dilution with Diluent prior to addition to the', 'infusion bag. A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The', 'diluent for TAXOTERE contains 13% ethanol in water for injection, and is supplied in vials.', '7.2.2', 'Preparation and Administration', 'The docetaxel should be dosed and administered per institutional standards in accordance with', 'FDA approved usage. Cycles should be repeated approximately every 3 weeks for 6 cycles.', 'Treatment delays and potential dose modifications will occur per standard of care at the', 'discretion of the treating physician, to reflect the clinical setting as much as possible.', 'The recommended pre-medication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and', '1 hour before the docetaxel infusion. However, other schedules or use of a different', 'corticosteroid is also acceptable consistent with local practice. Anti-emetic regimens are', 'recommended as per local clinical practice.', 'Preparation procedures are detailed in the package insert.', 'Page 23 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '7.3', 'Zytiga (Abiraterone)', '7.3.1', 'How Supplied, Stored, Packaged and Labeled', 'Zytiga', '250 mg tablets are white to off-white, oval tablets debossed with AA250 on one side. Zytiga', '250 mg tablets are available in high-density polyethylene bottles of 120 tablets.', 'Store at 20\u00b0 C to 25\u00b0 C (68\u00b0 F to 77\u00b0 F); excursions permitted to 15\u00b0 C to 30\u00b0 C (59\u00b0 F to 86\u00b0F).', 'Based on its mechanism of action, Zytiga may harm a developing fetus. Therefore, women', 'who are pregnant or women who may be pregnant should not handle Zytiga without protection', '(e.g., gloves).', 'Yonsa', 'Tablets, 125 mg, are white to off-white, oval-shaped tablets debossed with \"125 FP\" on one', 'side.', 'Store at 20\u00b0 C to 25\u00b0 C (68\u00b0 F to 77\u00b0 F); excursions permitted to 15\u00b0 C to 30\u00b0 C (59\u00b0 F to 86\u00b0F).', 'Women who are pregnant or women who may be pregnant should not handle Yonsa without', 'protection, e.g., gloves.', '7.3.2', 'Preparation and Administration', 'Zytiga', 'The Zytiga should be dosed and administered per institutional standards and in accordance', 'with FDA approved use. The package insert recommends 1,000 mg administered orally once', 'daily in combination with prednisone 5 mg administered orally twice daily. No food should be', 'consumed for at least two hours before the dose of Zytiga is taken and for at least one hour', 'after the dose of Zytiga is taken.', 'Yonsa', 'The Yonsa should be dosed and administered per institutional standards and in accordance', 'with FDA approved use. The recommended dose of YONSA is 500 mg (four 125 mg tablets)', 'administered orally once daily in combination with methylprednisolone 4 mg administered', 'orally twice daily with or without food.', '7.3.3', 'Accountability and Compliance', 'Abiraterone tablets will be supplied per standard practice of the treating physician and', 'pharmacy.', '7.4', 'Concomitant Medications and Therapies', '7.4.1', 'Prohibited Therapy', '7.4.1.1 Docetaxel', 'Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabolism of', 'docetaxel may be modified by the concomitant administration of compounds that', 'induce, inhibit, or are metabolized by cytochrome P450 3A4. In vivo studies showed', 'Page 24 of 52']\n\n###\n\n", "completion": "END"}